152 related articles for article (PubMed ID: 2457546)
1. Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
Fujita T; Shinkai Y; Inoue T; Tamura N
Immunology; 1988 Jul; 64(3):369-74. PubMed ID: 2457546
[TBL] [Abstract][Full Text] [Related]
2. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
Ito S; Tamura N; Fujita T
Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
[TBL] [Abstract][Full Text] [Related]
3. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
4. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
Mold C; Walter EI; Medof ME
J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
[TBL] [Abstract][Full Text] [Related]
5. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
Coyne KE; Hall SE; Thompson S; Arce MA; Kinoshita T; Fujita T; Anstee DJ; Rosse W; Lublin DM
J Immunol; 1992 Nov; 149(9):2906-13. PubMed ID: 1383332
[TBL] [Abstract][Full Text] [Related]
6. Additional forms of human decay-accelerating factor (DAF).
Seya T; Farries T; Nickells M; Atkinson JP
J Immunol; 1987 Aug; 139(4):1260-7. PubMed ID: 2440950
[TBL] [Abstract][Full Text] [Related]
7. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
8. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase.
Kameyoshi Y; Matsushita M; Okada H
Immunology; 1989 Dec; 68(4):439-44. PubMed ID: 2481641
[TBL] [Abstract][Full Text] [Related]
9. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.
Brodbeck WG; Liu D; Sperry J; Mold C; Medof ME
J Immunol; 1996 Apr; 156(7):2528-33. PubMed ID: 8786315
[TBL] [Abstract][Full Text] [Related]
10. Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes.
Kinoshita T; Medof ME; Nussenzweig V
J Immunol; 1986 May; 136(9):3390-5. PubMed ID: 2420889
[TBL] [Abstract][Full Text] [Related]
11. Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical c3 convertase, C4b,2a.
Nicholson-Weller A; Burge J; Austen KF
J Immunol; 1981 Nov; 127(5):2035-9. PubMed ID: 6913607
[TBL] [Abstract][Full Text] [Related]
12. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland.
Lass JH; Walter EI; Burris TE; Grossniklaus HE; Roat MI; Skelnik DL; Needham L; Singer M; Medof ME
Invest Ophthalmol Vis Sci; 1990 Jun; 31(6):1136-48. PubMed ID: 1693916
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.
Harris CL; Morgan BP
Immunology; 1995 Oct; 86(2):311-8. PubMed ID: 7490134
[TBL] [Abstract][Full Text] [Related]
14. Complement activation induces the expression of decay-accelerating factor on human mesangial cells.
Shibata T; Cosio FG; Birmingham DJ
J Immunol; 1991 Dec; 147(11):3901-8. PubMed ID: 1719094
[TBL] [Abstract][Full Text] [Related]
15. Homologous species restriction of the complement-mediated killing of nucleated cells.
Yamamoto H; Blaas P; Nicholson-Weller A; Hänsch GM
Immunology; 1990 Aug; 70(4):422-6. PubMed ID: 1697561
[TBL] [Abstract][Full Text] [Related]
16. A high m.w. form of decay-accelerating factor (DAF-2) exhibits size abnormalities in paroxysmal nocturnal hemoglobinuria erythrocytes.
Kinoshita T; Rosenfeld SI; Nussenzweig V
J Immunol; 1987 May; 138(9):2994-8. PubMed ID: 2437202
[TBL] [Abstract][Full Text] [Related]
17. Decay-accelerating factor functions as a signal transducing molecule for human monocytes.
Shibuya K; Abe T; Fujita T
J Immunol; 1992 Sep; 149(5):1758-62. PubMed ID: 1380538
[TBL] [Abstract][Full Text] [Related]
18. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
19. A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.
Santi P; Joiner KA; Hammer CH; Frank MM; Tosi R
J Immunol; 1987 May; 138(10):3385-91. PubMed ID: 2952716
[TBL] [Abstract][Full Text] [Related]
20. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis.
Mason JC; Lidington EA; Yarwood H; Lublin DM; Haskard DO
Arthritis Rheum; 2001 Jan; 44(1):138-50. PubMed ID: 11212152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
